Do peptides help with cognitive decline and nootropic use?
5 peptides are graded for cognitive decline and nootropic use on this page. The strongest grade is human RCT evidence, for cerebrolysin. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for cognitive decline and nootropic use?
Evaluation for reversible causes; management of vascular risk factors, sleep, hearing, and depression; cholinesterase inhibitors and memantine for Alzheimer disease; anti-amyloid antibodies in selected early cases.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for cognitive decline and nootropic use?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Cerebrolysin | Evidence: Human RCT evidence | Small trials in stroke and dementia with mixed results; not FDA approved. [1] |
| Semax | Evidence: Human observational evidence | Approved in Russia; Russian clinical reports; no indexed RCT; PCAC recommended for the 503A bulks list in July 2026. [1] |
| Selank | Evidence: Human observational evidence | Approved in Russia for anxiety; no indexed RCT. [1] |
| Noopept | Evidence: Human observational evidence | Not a peptide in the strict sense (dipeptide derived); Russian clinical reports only. [3] |
| Dihexa | Evidence: Animal-only evidence | Rodent studies only; no human safety data. [1] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
Which peptide has the strongest evidence for cognitive decline and nootropic use?
Cerebrolysin has the strongest evidence among the peptides graded here, at human RCT evidence. Small trials in stroke and dementia with mixed results; not FDA approved. [1]
Is any peptide FDA approved for cognitive decline and nootropic use?
No. None of the peptides graded for cognitive decline and nootropic use is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [4]
Has any peptide been tested in a randomized trial for cognitive decline and nootropic use?
Yes, for cerebrolysin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1]
From the blog
- Semax nasal spray: what the intranasal studies show
Semax was developed in Russia as nasal drops. What the intranasal stroke and imaging studies measured, how nasal and injected data compare, and what the July 2026 PCAC vote means.
Sources
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]PubMed search: cerebrolysin randomized controlled trial2026
- [3]Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic originPubMed 19234797, 2009
- [4]Drugs@FDA: FDA-approved drugs databaseFDA